Author: Cardozo, Timothy; Veazey, Ronald
Title: Informed consent disclosure to vaccine trial subjects of risk of COVIDâ€19 vaccines worsening clinical disease Cord-id: gw9hkw00 Document date: 2020_10_28
ID: gw9hkw00
Snippet: AIMS OF THE STUDY: Patient comprehension is a critical part of meeting medical ethics standards of informed consent in study designs. The aim of the study was to determine if sufficient literature exists to require clinicians to disclose the specific risk that COVIDâ€19 vaccines could worsen disease upon exposure to challenge or circulating virus. METHODS USED TO CONDUCT THE STUDY: Published literature was reviewed to identify preclinical and clinical evidence that COVIDâ€19 vaccines could wor
Document: AIMS OF THE STUDY: Patient comprehension is a critical part of meeting medical ethics standards of informed consent in study designs. The aim of the study was to determine if sufficient literature exists to require clinicians to disclose the specific risk that COVIDâ€19 vaccines could worsen disease upon exposure to challenge or circulating virus. METHODS USED TO CONDUCT THE STUDY: Published literature was reviewed to identify preclinical and clinical evidence that COVIDâ€19 vaccines could worsen disease upon exposure to challenge or circulating virus. Clinical trial protocols for COVIDâ€19 vaccines were reviewed to determine if risks were properly disclosed. RESULTS OF THE STUDY: COVIDâ€19 vaccines designed to elicit neutralizing antibodies may sensitize vaccine recipients to more severe disease than if they were not vaccinated. Vaccines for SARS, MERS and RSV have never been approved, and the data generated in the development and testing of these vaccines suggest a serious mechanistic concern: that vaccines designed empirically using the traditional approach (consisting of the unmodified or minimally modified coronavirus viral spike to elicit neutralizing antibodies), be they composed of protein, viral vector, DNA or RNA and irrespective of delivery method, may worsen COVIDâ€19 disease via antibodyâ€dependent enhancement (ADE). This risk is sufficiently obscured in clinical trial protocols and consent forms for ongoing COVIDâ€19 vaccine trials that adequate patient comprehension of this risk is unlikely to occur, obviating truly informed consent by subjects in these trials. CONCLUSIONS DRAWN FROM THE STUDY AND CLINICAL IMPLICATIONS: The specific and significant COVIDâ€19 risk of ADE should have been and should be prominently and independently disclosed to research subjects currently in vaccine trials, as well as those being recruited for the trials and future patients after vaccine approval, in order to meet the medical ethics standard of patient comprehension for informed consent.
Search related documents:
Co phrase search for related documents- ade immunopathology and lung injury: 1
Co phrase search for related documents, hyperlinks ordered by date